Reply to letter from Alvarez et al
| Errataetall: |
CommentOn: Hum Vaccin Immunother. 2020 Sep 1;16(9):2238-2244. - PMID 32040379 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 17(2021), 3 vom: 04. März, Seite 696-697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruiz-Aragón, Jesús [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Burden of illness |
|---|
| Anmerkungen: |
Date Completed 23.06.2021 Date Revised 30.10.2021 published: Print-Electronic CommentOn: Hum Vaccin Immunother. 2020 Sep 1;16(9):2238-2244. - PMID 32040379 Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2020.1813485 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316898910 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316898910 | ||
| 003 | DE-627 | ||
| 005 | 20231226202122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2020.1813485 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316898910 | ||
| 035 | |a (NLM)33121349 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruiz-Aragón, Jesús |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reply to letter from Alvarez et al |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2021 | ||
| 500 | |a Date Revised 30.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Hum Vaccin Immunother. 2020 Sep 1;16(9):2238-2244. - PMID 32040379 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Quadrivalent influenza vaccine (QIV) | |
| 650 | 4 | |a Spain | |
| 650 | 4 | |a burden of illness | |
| 650 | 4 | |a cell-based vaccines | |
| 650 | 4 | |a costeffectiveness | |
| 650 | 4 | |a high-risk | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a Gani, Ray |e verfasserin |4 aut | |
| 700 | 1 | |a Márquez, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Piedad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 17(2021), 3 vom: 04. März, Seite 696-697 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:3 |g day:04 |g month:03 |g pages:696-697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2020.1813485 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 3 |b 04 |c 03 |h 696-697 | ||